Clinical Trial Detail

NCT ID NCT02792192
Title Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-risk Non-muscle-invasive Bladder Cancer (NMIBC) Participants
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

bladder urothelial carcinoma

Therapies

Atezolizumab + BCG solution

Atezolizumab

Age Groups: adult

No variant requirements are available.